Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8N371

UPID:
KDM8_HUMAN

ALTERNATIVE NAMES:
JmjC domain-containing protein 5; Jumonji C domain-containing protein 5; L-arginine (3R)-hydroxylase KDM8

ALTERNATIVE UPACC:
Q8N371; B4DLU9; Q6VAK5; Q9H8B1

BACKGROUND:
The protein Bifunctional peptidase and arginyl-hydroxylase JMJD5, with alternative names such as Jumonji C domain-containing protein 5, is integral to cellular function. It uniquely combines endopeptidase and monooxygenase activities to modulate histone modification and gene expression. This protein's role in DNA damage response, mitotic spindle organization, and cell cycle control is crucial for maintaining genomic stability and cellular integrity.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted functions of Bifunctional peptidase and arginyl-hydroxylase JMJD5 offers a promising avenue for drug discovery. Its critical involvement in processes like mitosis and transcriptional regulation makes it a compelling target for developing novel treatments for cancer and other conditions characterized by abnormal cell growth and division.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.